title: [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
abstract: Successful Crohn's disease conservative treatment is often associated with use of few, sometimes new drugs. Their clinical use apart from inflammatory process decrease is associated with some risk. In the paper we report a case of 23-year-old woman suffering from Crohn's disease treated successfully with anti-TNF antibodies. Apart from successful anti-inflammatory there were observed not symptomatic perforation of the alimentary tract. Patients treated with strong anti-inflammatory drugs require especially careful monitoring also because of possibility of occurrence of not symptomatic life-threatening conditions.
authors.affiliation: Military Institute of Health Services in Warsaw, Central Clinical Hospital of the Ministry of National Defense, Department of Gastroenterology and Department of Tranfusiology. ljaloch@yahoo.com
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Jałocha
authors.forename: Stanisław
authors.initials: S
authors.lastname: Wojtuń
authors.forename: Marek
authors.initials: M
authors.lastname: Wojtkowiak
authors.forename: Antoni
authors.initials: A
authors.lastname: Błaszak
authors.forename: Przemysław
authors.initials: P
authors.lastname: Dyrla
authors.forename: Jerzy
authors.initials: J
authors.lastname: Gil
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000000981:diagnostic imaging; D007421:Intestine, Small / Q000000981:diagnostic imaging; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014463:Ultrasonography
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab